Laura Rosiñol Dachs

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2019 · 62 citations

Medicine, Hematology, Oncology +11

Integrated Analysis of Randomized Controlled Trials Evaluating Bortezomib + Lenalidomide + Dexamethasone or Bortezomib + Thalidomide + Dexamethasone Induction in Transplant-Eligible Newly Diagnosed Multiple Myeloma

Laura Rosiñol Dachs, Benjamin Hébraud, Albert Oriol et al. · Blood · 2018 · 22 citations

Medicine, Hematology, Oncology +16

Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Post-Hoc Analysis of Sustained Undetectable Measurable Residual Disease (MRD)

María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero et al. · Blood · 2022 · 22 citations

Medicine, Hematology, Oncology +14

VTD (Bortezomib/Thalidomide/Dexamethasone) As Pretransplant Induction Therapy for Multiple Myeloma: Definitive Results of a Randomized Phase 3 Pethema/GEM Study

Laura Rosiñol Dachs, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2018 · 15 citations

Medicine, Hematology, Oncology +15

Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)

María‐Victoria Mateos, Enrique M. Ocio, Anna Sureda et al. · Blood · 2020 · 14 citations

Medicine, Pharmacology, Pharmacotherapy +16